| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
|
Purity: ≥98%
Bestatin (also called Ubenimex; NK421; NSC 265489) is a potent, naturally occuring and broad-spectrum aminopeptidase-B and leukotriene (LT) A4 hydrolase inhibitor used in the treatment of acute myelocytic leukemia. Bestatin is isolated from the culture filtrate of Streptomyces olivoreticuli MD976-C7. The structure of bestatin was elucidated to be (2S, 3R)-3-amino-2-hydroxy-4- phenylbutanoyll-(S)-leucine. Bestatin itself was not hydrolyzed by either of the enzymes, when bestatin was incubated as substrate, L-leucine was not detected by thin-layer chromatography. Bestatin inhibits proliferation of all the human leukemic cell lines except KG1. Bestatin induces DNA fragmentation quantitatively and DNA ladder and enhances caspase-3 activity in U937 cells. Bestatin dose-dependently induces DNA fragmentation in human leukemic cell lines.
| ln Vitro |
In ATRA-sensitive APL NB4 cells, bestatin promotes ATRA-induced differentiation and prevents ATRA-driven activation of p38 MAPK. ATRA-resistant APL MR2 cells have a differentiation block that is not reversible by bestatin. When CD13 is ligated with the anti-CD13 antibody WM-15, p38 MAPK is phosphorylated, Bestatin's suppression of p38 MAPK phosphorylation is lessened, and the enhancement of Bestatin on ATRA-inducing differentiation in NB4 cells is entirely eliminated[2]. Cells treated with bestatin (600 μM) undergo delayed cell cycle progression because their frequency and growth rate of division are reduced. Bestatin suppresses D's innate multinuclearity and the frequency of mitosis. discoideum and does not cause D cytotoxicity. cells of discoideum at 0-600 μM. In the lysates of PsaA-GFP- and GFP-expressing cells, bestatin suppresses aminopeptidase activity by 69.39% and 39.93% of control, respectively[4].
|
||
|---|---|---|---|
| ln Vivo |
Bestatin (20 μM) effectively lowers CD13 expression in diabetic mice and generates a considerable suppression of MMP-9 specific gelationolytic band densities compared to diabetes vehicle-treated mice. Bestatin therapy dramatically reduces the expression of VEGF and heparanase in diabetic mice. Intravitreal bestatin therapy dramatically downregulates the expression of both HIF-1α and VEGF in diabetic mice retinas. Furthermore, the increased expression of heparanase in diabetic mice retinas is dramatically reduced by intravitreal bestatin treatment[1]. Bestatin (10, 1, and 0.1mg/kg, ip) therapy before the antigen-potentiated humoral response to SRBC leads in an enhanced number of splenocytes producing hemolytic anti-SRBC antibodies (PFC) and the 2-ME-resistant serum hemagglutinin titer (at a dose of 0.1 mg/kg). Bestatin (1 and 0.1 mg/kg) administered to mice five times on alternate days after cyclophosphamide injection does not change the suppressive effect of the drug regarding the number of PFC, and even causes the further decrease of the total anti-SRBC hemagglutinins at dose of 1 mg/kg on day 7 after antigen stimulation[3].
|
||
| Animal Protocol |
|
||
| References |
|
||
| Additional Infomation |
Ubenimex (also known as bestatin) is a competitive protease inhibitor. It is an inhibitor of aminopeptidase B, leukotriene A4 hydrolase, aminopeptidase N. It is being studied for use in the treatment of acute myelocytic leukemia.
Ubenimex has been reported in Streptomyces abikoensis and Streptomyces olivoreticuli with data available. Ubenimex is a microbial metabolite and dipeptide with potential immunomodulatory and antitumor activities. Ubenimex competitively inhibits many aminopeptidases, including B, N and leucine aminopeptidases. Aminopeptidases has been implicated in the process of cell adhesion and invasion of tumor cells. Therefore, inhibiting aminopeptidases may partially attribute to the antitumor effect of ubenimex. This agent also activates T lymphocyte, macrophage and bone marrow stem cell as well as stimulates release of interleukin-1 and -2, thus further enhances its antitumor activity. Drug Indication An adjuvant therapy used for acute and chronic myelonous leukemia, lung cancer and nasopharyngeal cancer. It is also used to treat hypercholesterolaemia. |
| Molecular Formula |
C16H24N2O4
|
|
|---|---|---|
| Molecular Weight |
308.37
|
|
| Exact Mass |
308.173
|
|
| CAS # |
58970-76-6
|
|
| Related CAS # |
Bestatin hydrochloride;65391-42-6;Bestatin trifluoroacetate;223763-80-2
|
|
| PubChem CID |
72172
|
|
| Appearance |
White to off-white solid powder
|
|
| Density |
1.2±0.1 g/cm3
|
|
| Boiling Point |
604.7±55.0 °C at 760 mmHg
|
|
| Melting Point |
245 °C (dec.)(lit.)
|
|
| Flash Point |
319.5±31.5 °C
|
|
| Vapour Pressure |
0.0±1.8 mmHg at 25°C
|
|
| Index of Refraction |
1.557
|
|
| LogP |
2.64
|
|
| Hydrogen Bond Donor Count |
4
|
|
| Hydrogen Bond Acceptor Count |
5
|
|
| Rotatable Bond Count |
8
|
|
| Heavy Atom Count |
22
|
|
| Complexity |
367
|
|
| Defined Atom Stereocenter Count |
3
|
|
| SMILES |
CC(C)C[C@@H](C(=O)O)NC(=O)[C@H]([C@@H](CC1=CC=CC=C1)N)O
|
|
| InChi Key |
VGGGPCQERPFHOB-RDBSUJKOSA-N
|
|
| InChi Code |
InChI=1S/C16H24N2O4/c1-10(2)8-13(16(21)22)18-15(20)14(19)12(17)9-11-6-4-3-5-7-11/h3-7,10,12-14,19H,8-9,17H2,1-2H3,(H,18,20)(H,21,22)/t12-,13+,14+/m1/s1
|
|
| Chemical Name |
(2S)-2-[[(2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl]amino]-4-methylpentanoic acid
|
|
| Synonyms |
|
|
| HS Tariff Code |
2934.99.9001
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 0.83 mg/mL (2.69 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 8.3 mg/mL clear DMSO stock solution to 400 μL of PEG300 and mix evenly; then add 50 μL of Tween-80 to the above solution and mix evenly; then add 450 μL of normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 0.83 mg/mL (2.69 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 8.3 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 0.83 mg/mL (2.69 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.2429 mL | 16.2143 mL | 32.4286 mL | |
| 5 mM | 0.6486 mL | 3.2429 mL | 6.4857 mL | |
| 10 mM | 0.3243 mL | 1.6214 mL | 3.2429 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA